Content

List volumes - List articles in this issue

Investigative Report

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

doi: 10.2340/00015555-2047

Abstract:

Pruritus is an important symptom in psoriasis with no targeted treatment. Tropomyosin-receptor kinase A (TrkA) is associated with pruritus and psoriatic plaque formation. We report the efficacy of a TrkA inhibitor, CT327, on pruritus in psoriasis. A randomised, double-blind, vehicle-controlled Phase 2b clinical trial was conducted in 160 subjects. No effect was found on psoriasis severity using Investigator’s Global Assessment (primary endpoint). However, clinically and statistically significant reductions in pruritus were observed in the 108 patient subset reporting at least moderate pruritus at baseline (37.1 mm visual analogue scale improvement (95% CI [–37.5, –6.2], p = 0.0067) for lowest dose; secondary endpoint). Significant modified Psoriasis Area and Severity Index reductions were found in this subset (p < 0.05). Experiments exploring capsaicin-mediated calcium influx, important in pruritus signalling, were performed in sensory neurons. CT327 inhibited capsaicin responses, indicating action at the nerve growth factor-TrkA-TRPV1 pathway. TrkA is a key target in pruritus, and CT327 has potential to become an effective and safe first-in-class treatment

Authors:

David Roblin, Gil Yosipovitch, Brent Boyce, John Robinson, James Sandy, Valentina Mainero, Ro Wickramasinghe, Uma Anand, Praveen Anand

References

1. Yosipovitch G, Goon A, Wee J, Chan YW, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969–973.

2. Prignano F, Ricceri F, Pescitelli L, Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin, Cosm Invest Derm 2009; 2: 9–13.

3. Reich A, Hrehorów E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010; 90: 257–263.

4. McCoy ES, Taylor-Blake B, Zylka MJ. CGRP-expressing sensory neurons respond to stimuli that evoke sensations of pain and itch. PLOS One 2012; 9: 1–11.

5. Han L, Ma C, Liu Q, Weng HJ, Cui Y, Tang Z, et al. A subpopulation of nociceptors specifically linked to itch. Nature Neuroscience 2013; 16: 174–182.

6. Rukweid RR, Main M, Weinkauf B, Schmelz M. NGF sensitizes nociceptors for cowhage- but not histamine induced itch in human skin. J Invest Dermatol 2013; 133: 268–270.

7. Raap U, Stander S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011; 11: 420–427.

8. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, neuroimmunological and neuroendocrine basis of pruritis. J Invest Dermatol 2006; 126: 1705–1718.

9. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, et al. The cloned capsaicin receptor integrates multiple pain producing stimuli. Neuron 1998; 21: 531–543.

10. Winter J, Forbes CA, Sternberg J, Lindsay RM. Nerve growth factor regulates the adult rat cultured dorsal root ganglion neuron responses to the excitotoxin capsaicin. Neuron 1988; 1: 973–981.

11. Anand U, Otto WR, Casula MA, Day NC, Davis JB, Bountra C, et al. The effect of neurotrophic factors on morphology, TRPV1 expression and capsaicin responses of cultured human DRG sensory neurons. Neurosci Lett 2006; 399: 51–56.

12. Bley K, Anand P. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107: 490–502.

13. Anand P, Foley P, Navsaria HA, Sinicropi D, Williams-Chestnut RE, Leigh IM. Nerve growth factor levels in cultured human skin cells: effect of gestation and viral transformation. Neurosci Lett 1995; 184: 157–160.

14. Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. Prog Brain Res 2004; 146: 477–492.

15. Bracci-Laudiero L, Pincelli C. Nerve growth factor is increased in psoriatic skin. J Invest Dermatol 1995; 105: 854–855.

16. Nakamura M, Toyoda M, Morahashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003; 149: 718–730.

17. Yamaguchi J, Aihara M, Kobayashi Y, Kambara T, Ikezawa Z. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatological Science 2009; 53: 48–54.

18. Anand U, Otto WR, Anand P. Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. Mol Pain 2010; 6: 1–11.

19. Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008; 138: 667–680.

20. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497–501.

21. Bautista D, Wilson S, Hoon M, Why we scratch an itch: the molecules, cells and circuits of itch. Nat Neurosci 2014; 17: 175–182.

22. Szepietowski C, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 2002; 10: 221–226.

23. Fleming C, Ganslandt C, Guenther L, Johannesson A, Buckley C, Simon JC, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double blind, exploratory study. Eur J Dermatol 2010; 20: 465–471.

24. Gibson R, Robertson J, Mistry H, McCallum S, Fernando D, Wyres M, Yosipovitch G. Randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. PLOS One 2014; 9: 1–11.

25. Ghilardi J, Freeman K, Jimenez-Andrade J, Mantyh W, Bloom A, Bouhana K, et al. Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone 2011; 48: 389–398.

26. Indo Y. Nerve growth factor, pain, itch and inflammation: lessons from congenital insensitivity to pain with anhidrosis. Exp Rev Neurother 2010; 10: 1707–1724.

27. Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol 2014; 70: 390–391.

28. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2013 Jan 7. doi: 10.1111/jdv.12081 [Epub ahead of print].

29. Lebwohl M, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley R, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871–881.

Related articles

There are no related articles.


Share with your friends





Actions


Abstract

Full text

PDF

Supplementary


Appendix SI
Figure S1
Table SI
Table SII
Table SIII
Table SIV

Print information


Volume 95, Issue 5

DOI: 10.2340/00015555-2047

Pages: 542-548

View at PubMed